Division of Neurology, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Canada K1H 8L1.
Neuromuscul Disord. 2013 Feb;23(2):103-11. doi: 10.1016/j.nmd.2012.09.008. Epub 2012 Nov 6.
The clinical presentation, disease course, response to treatment, and long-term outcome of thirty childhood chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients are presented representing the largest cohort reported to date. Most children (60%) presented with chronic (>8-weeks) symptom-onset while a smaller proportion showed sub-acute (4-8 weeks) or acute (''GBS-like''; <4 weeks) onset of disease. No gender predilection was observed. The majority of patients had a relapsing (70%) versus a monophasic (30%) temporal profile. Most received initial IVIG monotherapy; 80% showing a good response. Long-term follow-up (mean=3.8 years) was available for 23 patients; 45% were off all immunomodulatory medications, demonstrating no detectable (55%) or minimal (43%) clinical deficits. Our data were compared with 11 previously published childhood CIDP series providing a comprehensive review of 143 childhood CIDP cases. The combined initial or first-line treatment response across all studies was favourable for IVIG (79% patients) and corticosteroids (84% patients). Response to first-line plasma exchange was poor (only 14% patients improved) although it may offer some transient or partial benefit as an adjuvant or temporary therapy for selected patients. The combined long-term outcome of our cohort and the literature reveals a favourable prognosis for most patients. The combined modified Rankin scale decreased from 3.7 (at presentation) to 0.7 (at last follow-up). This review provides important data pertaining to clinical course, treatment response and long-term outcome of this relatively uncommon paediatric autoimmune disease.
本文呈现了 30 例儿童慢性炎症性脱髓鞘性多发性神经病(CIDP)患者的临床表现、疾病过程、治疗反应和长期预后,这是迄今为止报告的最大队列。大多数儿童(60%)表现为慢性(>8 周)起病,而较小比例的儿童表现为亚急性(4-8 周)或急性(“GBS 样”;<4 周)起病。未观察到性别倾向。大多数患者具有复发型(70%)而非单相型(30%)的时间特征。大多数患者接受初始 IVIG 单药治疗;80%显示良好的反应。23 例患者可进行长期随访(平均=3.8 年);45%停用所有免疫调节药物,无明显(55%)或轻微(43%)临床缺陷。我们的数据与 11 项以前发表的儿童 CIDP 系列进行了比较,对 143 例儿童 CIDP 病例进行了全面回顾。所有研究中初始或一线治疗的总体反应均有利于 IVIG(79%的患者)和皮质类固醇(84%的患者)。一线血浆置换的反应较差(仅 14%的患者改善),尽管它可能作为辅助或临时治疗为某些患者提供一些短暂或部分益处。本队列和文献的长期综合结果表明大多数患者预后良好。综合改良 Rankin 量表从 3.7(就诊时)下降至 0.7(最后随访时)。本综述提供了有关该相对罕见的儿科自身免疫性疾病的临床过程、治疗反应和长期预后的重要数据。